0001144204-17-051153.txt : 20171003
0001144204-17-051153.hdr.sgml : 20171003
20171003160453
ACCESSION NUMBER: 0001144204-17-051153
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171003
FILED AS OF DATE: 20171003
DATE AS OF CHANGE: 20171003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GIRSCHWEILER THOMAS
CENTRAL INDEX KEY: 0001273547
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 171117804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taurus4757 GmbH
CENTRAL INDEX KEY: 0001603397
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 171117803
BUSINESS ADDRESS:
STREET 1: WISSMANNSTRASSE 15
CITY: ZURICH
STATE: V8
ZIP: CH 8057
BUSINESS PHONE: 414 43620406
MAIL ADDRESS:
STREET 1: WISSMANNSTRASSE 15
CITY: ZURICH
STATE: V8
ZIP: CH 8057
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC
CENTRAL INDEX KEY: 0000834365
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 943076866
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254011400
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: BIOLIFE SOLUTION INC
DATE OF NAME CHANGE: 20030113
FORMER COMPANY:
FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
v476390_4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-10-03
0
0000834365
BIOLIFE SOLUTIONS INC
BLFS
0001273547
GIRSCHWEILER THOMAS
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL
WA
98021
1
0
1
0
0001603397
Taurus4757 GmbH
ROOSSTRASSE 53
CH-8832 WOLLERAU
ZURICH
V8
CH 8057
SWITZERLAND
0
0
1
0
Common Stock
2017-10-03
4
A
0
887
A
2813843
I
By Taurus
The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.
/s/ Roderick de Greef, as attorney-in-fact for Thomas Girschweiler and Tauras4757 GmbH
2017-10-03